Getting your Trinity Audio player ready...

Jackson Center, PA, March 14, 2023 – Halberd Corporation (OTC: HALB) is scheduled to meet with Center of Disease Control (CDC) on March 29, 2023, to discuss the elimination of multiple strains of antibiotic resistant (AR) E. coli bacteria and Candida auris samples provided to Halberd from the CDC. The testing is currently underway at Youngstown State University (YSU) and Halberd’s patented extracorporeal laser eradication process eliminate over 90% of the CDC sample bacteria thus far. 

Trading Activity

HALB stock surged 9.54% on Tuesday on average volume.

Earlier this year Halberd Corporation had been sent samples of antibiotic-resistant antigens by the Center of Disease Control (CDC). Yesterday, the company announced that it was going to meet with the representatives from CDC to have a discussion on the stellar success that it had achieved in eradicating the E. Coli bacteria and Candida auris samples. The testing had been conducted by the company at Youngstown State University and through the use of its extracorporeal technology,

Halberd had been successful in eradicating in excess of 90% of the antibiotic resistant bacteria and fungus in less than 10 minutes. In comparison, eradication usually takes up to 10 days when injected or oral antibiotics are used.

Dr. Cooper, who is a Professor at the Department of Chemical and Biological Sciences at Youngstown State University and the company’s main conduit to the CDC, stated that everyone was anxious to report the findings to the CDC at a meeting that would be held later on this month on 29 March. The President, Chairman and Chief Executive Officer of Halberd William A Hartman spoke about the importance of the meeting as well.

He noted that the meeting with the CDC could be a major opportunity for Halberd to make a presentation of the superb results that had been achieved by the company to the experts on antibiotic-resistant bacteria at the CDC. He went on to add that the company would continue to contract other government agencies for the purpose of further developing its patented technology.